Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Cancer Agent ◽

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

10.1200/jco.2010.28.15_suppl.3528 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3528-3528 ◽

Cited By ~ 8

Author(s):

J. Douillard ◽

J. Cassidy ◽

J. Jassem ◽

F. Rivera ◽

I. Kocáková ◽

...

Keyword(s):

Colorectal Cancer ◽

Skin Toxicity ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Annals of Oncology ◽

10.1093/annonc/mdx816 ◽

2018 ◽

Vol 29 (3) ◽

pp. 624-631 ◽

Cited By ~ 21

Author(s):

Y. Yamada ◽

T. Denda ◽

M. Gamoh ◽

I. Iwanaga ◽

S. Yuki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Noninferiority Trial ◽

Open Label Phase ◽

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdz155.033 ◽

2019 ◽

Vol 30 ◽

pp. iv10

Author(s):

K. Muro ◽

H. Uetake ◽

K. Tsuchihara ◽

K. Shitara ◽

K. Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Phase Iii Study ◽

Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/− celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015

10.1200/jco.2005.23.16_suppl.3525 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3525-3525 ◽

Cited By ~ 12

Author(s):

C.-H. Kohne ◽

J. de Greve ◽

C. Bokemeyer ◽

I. Lang ◽

P. Vergauwe ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

Lung Cancer ◽

10.1016/j.lungcan.2012.05.043 ◽

2012 ◽

Vol 77 ◽

pp. S25-S26 ◽

Cited By ~ 18

Author(s):

Martin Schuler ◽

James Chih-Hsin Yang ◽

Nobuyuki Yamamoto ◽

Ken O’Byrne ◽

Vera Hirsh ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Activating Mutations ◽

Adenocarcinoma Of The Lung ◽

Open Label Phase ◽

Phase Iii Study ◽

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

10.1200/jco.2010.28.15_suppl.3529 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3529-3529 ◽

Cited By ~ 6

Author(s):

T. J. Price ◽

A. F. Sobrero ◽

G. Wilson ◽

E. Van Cutsem ◽

B. Aleknaviciene ◽

...

Keyword(s):

Colorectal Cancer ◽

Skin Toxicity ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

10.1200/jco.2014.32.15_suppl.8008 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8008-8008 ◽

Cited By ~ 18

Author(s):

Nick Thatcher ◽

Fred R. Hirsch ◽

Aleksandra Szczesna ◽

Tudor-Eliade Ciuleanu ◽

Wojciech Szafranski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.

10.1200/jco.2016.34.15_suppl.tps3625 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS3625-TPS3625 ◽

Cited By ~ 1

Author(s):

Kei Muro ◽

Hiroyuki Uetake ◽

Katsuya Tsuchihara ◽

Kohei Shitara ◽

Kentaro Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Phase Iii Study ◽